Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Case series of teclistamab in myeloma patients with secondary plasma cell leukemia (PCL) shows median PFS of only 27 days (responders had PFS of 4.6 months) and none of those with prior BCMA therapy exposure had a response.”
Title: The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia
Authors: Asis Shrestha, Sharmilan Thanendrarajan, Aishee Bag, Binod Dhakal, Maurizio Zangari, Samer Al Hadidi, Frits van Rhee, Anita D’Souza, Nishi Shah, Mansi R. Shah, Meera Mohan, Carolina Schinke.
You can read the Full Article in Blood Advances.
You can find more posts featuring Robert Orlowski in OncoDaily.
